PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pneumococcal vaccine: Overview • Vaccine approval process PART 06: Market landscape • Market overview • Five forces analysis • Market segmentation by composition • Global PCV market • Market overview • Global PPV market • Market overview PART 07: Geographical segmentation • Pneumococcal vaccine market in Americas • Pneumococcal vaccine market in EMEA • Pneumococcal vaccines market in APAC PART 08: Market drivers • Inclusion in NIP • Broad serotype coverage • Global action plans for pneumonia vaccines PART 09: Impact of drivers PART 10: Market challenges • Inadequate vaccine coverage • Require cold storage • High risk and cost involved in vaccine development • Stringent regulatory guidelines PART 11: Impact of drivers and challenges PART 12: Market trends • Expansion of marketing territories • Emergence of protein-based combination pneumococcal vaccines • AMC for pneumococcal vaccines • Bio-terrorism • Public–private initiatives PART 13: Vendor landscape • Competitive scenario • Key news • Pfizer • Sanofi • GSK • Merck • Other prominent vendors PART 14: Appendix • List of abbreviations PART 15: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Market share of pneumococcus vaccine market in global pharmaceutical market 2015 Exhibit 03: Market share of pneumococcal vaccine markets in global pharmaceutical market, 2015 Exhibit 04: Global pneumococcal vaccine market snapshot Exhibit 05: Milestones in pneumococcus vaccines development Exhibit 06: Key buying criteria for pneumococcal vaccine 2015 Exhibit 07: Impact of key customer segments on market 2015 Exhibit 08: Requirements for a BLA submission Exhibit 09: Types of development necessary to reach vaccine licensing stage Exhibit 10: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion Exhibit 11: Regulatory testing of licensed vaccines Exhibit 12: Economic burden of pneumococcal disease in children 2015 Exhibit 13: Total global costs for treating pneumococcal disease 2015 ($ billions) Exhibit 14: Global pneumococcal vaccine market snapshot: Developed and emerging markets 2015 Exhibit 15: Overview of vaccine-related acquisitions 2005-2012 Exhibit 16: Global pneumococcal vaccine market 2015-2020 ($ billions) Exhibit 17: Approved pneumococcal serotypes Exhibit 18: Global pneumococcal vaccines market by volume 2013-2020 (million doses) Exhibit 19: Impact of drivers and challenges on global pneumococcal vaccine market Exhibit 20: Five forces analysis Exhibit 21: Global pneumococcal vaccines market: Segmentation by composition 2015-2020 Exhibit 22: Global pneumococcal vaccines market segmentation by application 2015 Exhibit 23: Global pneumococcal vaccines market segmentation: Growth cycle analysis Exhibit 24: Global supply and demand of PCV ($ millions) (2010-2017) Exhibit 25: Price evolution of PCV (2009-2015) Exhibit 26: Global PCV market 2015-2020 ($ billions) Exhibit 27: Opportunity analysis of global conjugate vaccines market by composition Exhibit 28: Global PPV market 2015-2020 ($ billions) Exhibit 29: Opportunity analysis of global polysaccharide vaccines market by composition Exhibit 30: Global PPV market segmentation by composition 2015 Exhibit 31: Global pneumococcal vaccine market by geography 2015 Exhibit 32: Global pneumococcal vaccine market: Geographical outlook (2015-2020) Exhibit 33: Global pneumococcal vaccine market: Geographical outlook 2015 Exhibit 34: Segmentation of global pneumococcal vaccine market by region: Market growth lifecycle analysis 2015 Exhibit 35: Opportunity analysis of pneumococcal vaccine market in Americas Exhibit 36: Pneumococcal vaccine market in Americas 2015-2020 ($ billions) Exhibit 37: Pneumococcal vaccine market in Americas: PEST analysis Exhibit 38: Opportunity analysis of pneumococcal vaccine market in EMEA Exhibit 39: Pneumococcal vaccine market in EMEA 2015-2020 ($ billions) Exhibit 40: Pneumococcal vaccine market in EMEA: PEST analysis Exhibit 41: Opportunity analysis of pneumococcal vaccine market in APAC Exhibit 42: Pneumococcal vaccine market in APAC 2015-2020 ($ billions) Exhibit 43: Pneumococcal vaccine market in APAC: PEST analysis Exhibit 44: Impact of drivers Exhibit 45: A typical cold chain process Exhibit 46: Impact of drivers and challenges Exhibit 47: Global pneumococcal vaccines market: Impact assessment of key trends 2015 Exhibit 48: Developing countries and their approval status for GAVI support Exhibit 49: Pneumococcal procurement volumes through AMC (million doses) Exhibit 50: Geographical presence of top vendors in global pneumococcal vaccine market 2015 Exhibit 51: Competitive assessment of vendors Exhibit 52: Key vendors: Geographical presence 2015 Exhibit 53: Pfizer: YoY revenue and growth rate of Prevnar 2013-2015 ($ billions) Exhibit 54: Pfizer: Revenue forecast of Prevnar 2016-2020 ($ billions) Exhibit 55: Pfizer: Metrics analysis Exhibit 56: Sanofi: YoY revenue growth of Meningitis/pneumonia vaccines 2013-2015 ($ millions) Exhibit 57: Geographical segmentation of meningitis vaccines/PCVs by revenue 2015 Exhibit 58: Sanofi: Metrics analysis Exhibit 59: GSK: YoY revenue and growth rate of Synflorix 2013-2015 ($ millions) Exhibit 60: GSK: YoY geographical revenue of Synflorix 2013-2015 ($ millions) Exhibit 61: GSK: Geographical segmentation of Synflorix 2015 Exhibit 62: Synflorix price per dose in different countries Exhibit 63: GSK: Metrics analysis Exhibit 64: Merck: YoY revenue growth of Pneumovax 23 2013-2015 ($ millions) Exhibit 65: Merck: Metrics analysis

Pfizer, Sanofi, Merck, GSK, Abera, AstraZeneca, Baxter, Beijing Minhai Biotechnology, Biken, Biogen, Celgene, Eli Lilly, Genentech, Genocea Biosciences, ImmunoBiology, Lupin, Nuron Biotech, Panacea Biotec, S K Chemicals, Serum Institute of India, Sinovac, Valneva Austria.